One To Watch
Milestone Pharmaceuticals
Company Overview
A commercial-stage cardiovascular biopharmaceutical company whose self-administered etripamil nasal spray is approved in the US and China for paroxysmal supraventricular tachycardia, with a pivotal Phase III trial now enrolling in atrial fibrillation. Milestone trades on Nasdaq under the ticker MIST and frames its commercial thesis around one specific unmet need: giving patients a way to terminate acute arrhythmia episodes at home rather than in an emergency department. CARDAMYST is available through US retail pharmacies as of January 2026, and copays are capped at $25 for eligible commercially insured patients.
Headquarters and Global Presence
Milestone Pharmaceuticals operates from two offices: its corporate base in Montreal, Canada, and a US commercial base in Charlotte, North Carolina. The dual footprint reflects the company's origins in Canada alongside a dedicated US launch infrastructure built to support the CARDAMYST rollout.
Founding and History
Joseph Oliveto has served as President and CEO since March 2017, suggesting the company was organized well ahead of its commercial phase. The regulatory path to CARDAMYST's approval was protracted: the FDA issued a Refusal to File letter in December 2023, followed by a Complete Response Letter in March 2025 on chemistry, manufacturing and controls grounds only, before granting approval on December 12, 2025. Milestone entered the Chinese market by licensing etripamil to Ji Xing Pharmaceuticals in May 2021; that arrangement was later restructured through Everest Medicines, which now holds the Greater China license.
Therapy Areas and Focus
Milestone's entire commercial and development program is built around acute cardiac arrhythmias. CARDAMYST targets paroxysmal supraventricular tachycardia, a condition characterized by sudden, self-terminating episodes of rapid heart rate that have historically driven patients to emergency departments. The lead development program in atrial fibrillation with rapid ventricular rate would, if approved, address a substantially larger patient population with a similar clinical logic: rapid, unsupervised rate control at home.
Technology Platforms and Modalities
Etripamil is a calcium channel blocker formulated as a nasal spray for self-administration, providing rapid systemic absorption without intravenous access or clinical supervision. The mechanism slows conduction through the AV node, interrupting the re-entrant circuits that sustain supraventricular tachycardia. The nasal route is the commercially differentiating element: oral calcium channel blockers act too slowly for acute conversion, while intravenous adenosine requires clinical administration.
Key Pipeline and Programs
CARDAMYST (etripamil nasal spray, 70 mg) is approved in the US and China for conversion of acute PSVT episodes to sinus rhythm. The FDA approval was grounded in the Phase III RAPID trial, which showed 64% of etripamil-treated patients converted within 30 minutes versus 31% on placebo, with a median conversion time of 17 minutes against 54 minutes (hazard ratio 2.62; p less than 0.001). The China Phase III JX02002 study, run across 48 centers, produced a hazard ratio of 3.002 (95% CI 1.578 to 5.711; p equals 0.0005).
In Europe, the same product is under review by the European Medicines Agency under the brand name TACHYMIST, following EMA acceptance of the Marketing Authorization Application on January 6, 2026. An EMA decision is guided for the first half of 2027.
ReVeRA-301 is the pivotal Phase III study of etripamil in atrial fibrillation with rapid ventricular rate, with first patient enrolled on August 21, 2026. The multinational, randomized, double-blind, placebo-controlled study targets approximately 150 patients self-administering the same 70 mg repeat-dose regimen in unsupervised settings. The primary endpoint is ventricular rate reduction within 30 minutes; it follows Phase II ReVeRA-201 data that showed rate reduction and improved patient-reported symptom relief.
Recent Developments
The NMPA approved etripamil in China on September 3, 2026, marking the first ex-US regulatory clearance and triggering a $2.0 million milestone payment from Greater China licensee Everest Medicines. ReVeRA-301 enrolled its first patient on August 21, 2026. Second quarter 2026 results showed more than 1,500 prescriptions filled for more than 1,300 patients by more than 800 unique prescribers, with commercial covered lives growing to roughly 50% following formulary wins at UnitedHealthcare and other large commercial insurers. Cash stood at $170.6 million as of June 30, 2026, expected to fund operations into the second half of 2027.
Key Personnel
Joseph Oliveto serves as President and Chief Executive Officer, a position he has held since March 2017. David B. Bharucha, M.D., Ph.D., FACC serves as Chief Medical Officer, joining in February 2022; he commented on the ReVeRA-301 Phase III initiation in August 2026. Amit Hasija serves as Chief Financial Officer and Executive Vice President of Corporate Development, appointed in September 2019.
Strategic Partnerships
Everest Medicines holds the exclusive license to develop, manufacture and commercialize etripamil across Greater China, having acquired the rights from Corxel Pharmaceuticals on March 23, 2026 for an upfront payment of $30 million to Corxel plus up to $20 million in development milestones. Milestone is eligible to receive up to $98.0 million in further commercial and development milestones from Everest, plus tiered royalties of up to 18% on net sales in the territory. In Europe, no ex-European commercialization partner has been publicly named; Milestone is pursuing the EMA review independently with a decision targeted in the first half of 2027.
FAQ Section
PSVT affects an estimated 3 million to 6 million patients in China alone; the US population is in a similar range globally. The commercial logic is straightforward: patients have historically had no acute treatment option outside the emergency department, meaning each episode generates a high-cost institutional encounter. A pharmacy-dispensed nasal spray that converts episodes at home changes that dynamic, and Milestone's pricing model, with copays capped at $25 for eligible commercially insured patients, is designed to remove access friction early in the launch.
AV nodal re-entrant tachycardias require rapid pharmacological interruption; the window for conversion before symptoms drive a patient to seek emergency care is narrow. Oral calcium channel blockers absorb too slowly to be practical in that setting. Nasal delivery of etripamil achieves systemic exposure quickly enough to produce a median conversion time of 17 minutes in the RAPID trial, versus 54 minutes on placebo, without requiring intravenous access or medical supervision.
The main current alternatives are vagal maneuvers, which succeed inconsistently, and intravenous adenosine or verapamil, which require clinical administration. CARDAMYST is the first and only FDA-approved self-administered treatment for acute PSVT, and the pivotal RAPID trial safety database covered more than 1,800 participants across more than 2,000 episodes, supporting a credible benefit-risk profile for unsupervised use. The combination of a novel route and a meaningful efficacy signal in a large, controlled dataset is what secured approval after a regulatory process that absorbed both a Refusal to File letter and a Complete Response Letter.
ReVeRA-301 is a pivotal Phase III study targeting approximately 150 patients with atrial fibrillation with rapid ventricular rate, using the same 70 mg repeat-dose regimen already approved in PSVT. The primary endpoint is ventricular rate reduction within 30 minutes in a self-administered, unsupervised setting. AFib-RVR represents a substantially larger commercial opportunity than PSVT; a positive readout would allow Milestone to expand its single-asset franchise without requiring a new compound or new manufacturing infrastructure.
Milestone is entirely focused on acute cardiac arrhythmias, with no disclosed programs outside that space. The current pipeline spans two indications for the same molecule: PSVT, where CARDAMYST is approved and generating early commercial revenue, and AFib-RVR, now in Phase III. That concentration is both a strategic clarity and a risk concentration; the company's medium-term value is almost entirely indexed to etripamil's commercial performance and the ReVeRA-301 readout.
The company launched commercially in mid-February 2026 and by June 30, 2026 had filled more than 1,500 prescriptions for more than 1,300 patients across more than 800 prescribers. Cash of $170.6 million as of June 30, 2026 provides runway into the second half of 2027, which brackets the expected EMA decision on TACHYMIST and the ongoing ReVeRA-301 enrollment.
The watchpoints over the next 12 to 18 months include:
- EMA decision on TACHYMIST (etripamil) for PSVT, guided for the first half of 2027, which would open the European market.
- ReVeRA-301 enrollment pace and eventual Phase III readout in AFib-RVR, the most significant pipeline catalyst.
- Everest Medicines' China launch execution and whether commercial milestones are triggered on a timeline that supplements Milestone's own cash position.
- Concentration risk: the entire enterprise rests on a single molecule across two indications; any safety signal or reimbursement setback would have an outsized impact.
Latest Milestone Pharmaceuticals News
Today's issue
| Headless Content Management with Blaze